Categories Earnings, Health Care

Dynavax Technologies Corporation (NASDAQ: DVAX): Q4 2019 Earnings Snapshot

— Biopharmaceutical company Dynavax Technologies Corporation (NASDAQ: DVAX) reported a net loss of $36.8 million $0.44 per share for the fourth quarter of 2019, vs. $0.33 per share loss expected.

— Total sales more than doubled year-over-year to $10.57 million, vs. $11.96 million expected

— Research and development expenses dropped to $12.3 million in the fourth quarter from $22.9 million last year

— Established research collaboration with the University of Queensland and the Coalition for Epidemic Preparedness to develop coronavirus vaccine

— Appointed Ryan Spencer chief executive officer and to the board of directors; named David Novack president and chief operating officer

— Expects HEPLISAV-B net product revenue to increase to $55-$62 million in fiscal 2020

— On track to release interim data from ongoing study of HEPLISAV-B in hemodialysis patients in the first quarter

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top